Exact Sciences (EXAS) Competitors $59.40 +3.29 (+5.86%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EXAS vs. ALNY, BIIB, UTHR, NBIX, INCY, BMRN, EXEL, RGEN, MDGL, and HALOShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership. Is ALNY or EXAS more profitable? Exact Sciences has a net margin of -7.95% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-15.86% N/A -8.38% Exact Sciences -7.95%-6.17%-2.98% Does the media favor ALNY or EXAS? In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Exact Sciences. MarketBeat recorded 12 mentions for Alnylam Pharmaceuticals and 4 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 0.73 beat Alnylam Pharmaceuticals' score of 0.62 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, ALNY or EXAS? Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.09B15.11-$440.24M-$2.62-93.68Exact Sciences$2.69B4.08-$204.15M-$1.17-50.77 Which has more risk & volatility, ALNY or EXAS? Alnylam Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ALNY or EXAS? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Exact Sciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.4% of Exact Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate ALNY or EXAS? Alnylam Pharmaceuticals currently has a consensus price target of $298.09, suggesting a potential upside of 21.45%. Exact Sciences has a consensus price target of $72.94, suggesting a potential upside of 22.79%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.71Exact Sciences 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.94 Does the MarketBeat Community favor ALNY or EXAS? Alnylam Pharmaceuticals received 155 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.16% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.01% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes113476.16% Underperform Votes35523.84% Exact SciencesOutperform Votes97973.01% Underperform Votes36226.99% SummaryExact Sciences beats Alnylam Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.99B$2.93B$5.13B$9.07BDividend YieldN/A15.63%5.08%4.23%P/E Ratio-50.7716.0289.5817.17Price / Sales4.08284.461,116.12116.95Price / Cash3,708.60472.1142.8237.86Price / Book3.425.194.774.78Net Income-$204.15M-$32.86M$120.15M$225.60M7 Day Performance-3.02%-3.01%-1.92%-1.23%1 Month Performance11.26%2.96%11.47%3.36%1 Year Performance-16.84%12.37%30.54%16.60% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.4914 of 5 stars$59.40+5.9%$72.94+22.8%-11.7%$10.99B$2.69B-50.776,600ALNYAlnylam Pharmaceuticals4.4132 of 5 stars$245.31-0.1%$298.09+21.5%+37.1%$31.64B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6302 of 5 stars$150.99+0.6%$245.32+62.5%-41.0%$22.00B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7129 of 5 stars$370.79+2.5%$370.86+0.0%+59.5%$16.55B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8286 of 5 stars$134.40+6.1%$165.00+22.8%+12.6%$13.61B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7054 of 5 stars$70.46+2.8%$76.13+8.0%+13.3%$13.57B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9845 of 5 stars$65.89-0.2%$94.20+43.0%-29.1%$12.56B$2.75B39.533,401Positive NewsEXELExelixis4.5106 of 5 stars$36.02+2.8%$31.47-12.6%+43.4%$10.29B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.101 of 5 stars$159.52+2.0%$190.25+19.3%-19.7%$8.94B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2396 of 5 stars$309.23+1.6%$347.33+12.3%+39.5%$6.74BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Repligen Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EXAS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXAS Stock Alerts